Skip to main content
Clinical Trials/IRCT2017013132326N1
IRCT2017013132326N1
Completed
未知

Assessment the efficacy of augmentation Flavonoid Quercetin to risperidon in treatment of autism spectrum disorders

Vice Chancellor for Research of Mashhad University of Medical Sciences0 sites70 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Autism Spectrum Disorders.
Sponsor
Vice Chancellor for Research of Mashhad University of Medical Sciences
Enrollment
70
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice Chancellor for Research of Mashhad University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • The inclusion criteria: Of all patients with ASD, ranging in age from 3to 12years; Parent's Consent; No obvious organic disease; The lack of other psychiatric disorders; Not taking other psychoactive medications other than risperidone; IQ higher than 50 on the basis of Weiland test.
  • The exclusion criteria: In the absence of cooperation of parents after inclusion; the risk of any side effect or another disease that cause a problem in results.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials